SCHEMBL1708944

SCHEMBL1708944

C/C=C/C[C@@H](C)[C@@H](O)[C@@H]1C(=O)N[C@H](CC)C(=O)N(C)[C@H](CSCCN(CC)CC)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@H](C(C)C)C(=O)N(C)[C@H](CC(C)C)C(=O)N[C@H](C)C(=O)N[C@@H](C)C(=O)N(C)[C@H](CC(C)C)C(=O)N(C)[C@H](CC(C)C)C(=O)N(C)[C@H](C(C)C)C(=O)N1C

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPIA P62937 20/20 0.78
SLCO1B1 Q9Y6L6 4/20 0.74
ABCB11 O95342 2/20 0.74
ABCB1 P08183 2/20 0.74
ABCC2 Q92887 2/20 0.74
SLCO1B3 Q9NPD5 2/20 0.74
PPIB P23284 11/20 0.73
CYP3A4 P08684 2/20 0.72
CYP2C9 P11712 2/20 0.72
PPIF P30405 2/20 0.72
CYP2C19 P33261 2/20 0.72
MEN1 O00255 1/20 0.72
NPC1 O15118 1/20 0.72
ABCC3 O15438 1/20 0.72
GMNN O75496 1/20 0.72
USP2 O75604 1/20 0.72
SLCO2B1 O94956 1/20 0.72
LMNA P02545 1/20 0.72
POLB P06746 1/20 0.72
MAPT P10636 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16546031 1.00 PPIA (0.78) PPIASLCO1B1ABCB11ABCB1ABCC2
SCHEMBL15182917 1.00 PPIA (0.78) PPIASLCO1B1ABCB11ABCB1ABCC2
SCHEMBL15182919 1.00 PPIA (0.78) PPIASLCO1B1ABCB11ABCB1ABCC2
SCHEMBL15183399 0.99 PPIA (0.77) PPIASLCO1B1ABCB11ABCB1ABCC2
SCHEMBL19861427 0.99 PPIA (0.77) PPIASLCO1B1ABCB11ABCB1ABCC2
SCHEMBL15183393 0.97 PPIA (0.74) PPIASLCO1B1ABCB11ABCB1ABCC2
SCHEMBL19861430 0.96 PPIA (0.73) PPIASLCO1B1ABCB11ABCB1ABCC2
SCHEMBL1708969 0.96 PPIA (0.75) PPIASLCO1B1ABCB11ABCB1ABCC2
SCHEMBL1708946 0.96 PPIA (0.72) PPIASLCO1B1ABCB11ABCB1ABCC2
SCHEMBL16546034 0.96 PPIA (0.72) PPIASLCO1B1ABCB11ABCB1ABCC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9579385-B2 Ophthalmic compositions comprising polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymers ALLERGAN, INC. (US) 2017-02-28 US disclosed
US-20170029469-A1 CYCLOSPORIN ANALOGS ALLERGAN, INC. 2017-02-02 US disclosed
US-9493511-B2 Cyclosporin analogs ALLERGAN, INC. (US) 2016-11-15 US disclosed
US-20140128329-A1 OPHTHALMIC COMPOSITIONS COMPRISING POLYVINYL CAPROLACTAM-POLYVINYL ACETATE-POLYETHYLENE GLYCOL GRAFT COPOLYMERS ALLERGAN, INC. (US) 2014-05-08 US disclosed
US-20130157963-A1 OPHTHALMIC COMPOSITIONS COMPRISING POLYVINYL CAPRALACTAM-POLYVINYL ACETATE-POLYETHYLENE GLYCOL GRAFT COPOLYMERS ALLERGAN, INC. (US) 2013-06-20 US disclosed
US-20120088734-A1 Cyclosporin Analogs ALLERGAN, INC. (US) 2012-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130157963-A1 OPHTHALMIC COMPOSITIONS COMPRISING POLYVINYL CAPRALACTAM-POLYVINYL ACETATE-POLYETHYLENE GLYCOL GRAFT COPOLYMERS PDE6D, UACA, ADCYAP1R1 PPIA 381/4885SLCO1B1 1771/4885ABCB11 3443/4885
US-20120088734-A1 Cyclosporin Analogs CHP1, TSLP, PPP3R1 PPIA 202/4885SLCO1B1 1324/4885ABCB11 2040/4885
US-20170029469-A1 CYCLOSPORIN ANALOGS CHP1, TSLP, PPP3R1 PPIA 202/4885SLCO1B1 1324/4885ABCB11 2040/4885
US-20140128329-A1 OPHTHALMIC COMPOSITIONS COMPRISING POLYVINYL CAPROLACTAM-POLYVINYL ACETATE-POLYETHYLENE GLYCOL GRAFT COPOLYMERS PDE6D, PDE6C, UACA PPIA 413/4885SLCO1B1 1716/4885ABCB11 2979/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.